Table 2.
Training cohort | Validation cohort | Entire cohort | ||||
---|---|---|---|---|---|---|
Hazard ratio | P | Hazard ratio | P | Hazard ratio | P | |
Immunoscore* | 1·92 (1·54, 2·40) | < 0·001 | 1·81 (1·17, 2·79) | 0·008 | 1·89 (1·56, 2·30) | < 0·001 |
Age* | 1·02 (1·01, 1·04) | < 0·001 | 1·02 (1·00, 1·04) | 0·069 | 1·02 (1·01, 1·03) | < 0·001 |
Tumour stage | < 0·001 | < 0·001 | < 0·001 | |||
I | 1·00 (reference) | 1·00 (reference) | 1·00 (reference) | |||
II | 3·23 (1·24, 8·41) | 0·016 | 2·12 (0·71, 6·34) | 0·179 | 2·75 (1·35, 5·64) | 0·006 |
III | 7·85 (3·14, 19·62) | < 0·001 | 2·59 (0·88, 7·59) | 0·083 | 5·36 (2·69, 10·67) | < 0·001 |
IV | 22·21 (8·85, 55·73) | < 0·001 | 6·58 (2·25, 19·19) | 0·001 | 14·34 (7·18, 28·64) | < 0·001 |
Laurén classification | 0·391 | 0·670 | 0·536 | |||
Intestinal | 1·00 (reference) | 1·00 (reference) | 1·00 (reference) | |||
Diffuse | 1·41 (0·86, 2·33) | 0·177 | 1·09 (0·52, 2·25) | 0·825 | 1·18 (0·78, 1·76) | 0·433 |
Mixed | 1·04 (0·75, 1·42) | 0·825 | 1·26 (0·76, 2·10) | 0·374 | 1·11 (0·85, 1·44) | 0·458 |
Values in parentheses are 95 per cent confidence intervals.
Continuous variable.